vs

Side-by-side financial comparison of Alarm.com Holdings, Inc. (ALRM) and BIOCRYST PHARMACEUTICALS INC (BCRX). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($406.6M vs $261.7M, roughly 1.6× Alarm.com Holdings, Inc.). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 13.2%, a 47.2% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs 8.0%). BIOCRYST PHARMACEUTICALS INC produced more free cash flow last quarter ($291.2M vs $35.1M). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 8.3%).

Alarm.com, Inc. is an American technology company that provides cloud-based services for remote control, home automation, and alarm monitoring services. The company was founded in 2000 as a spinoff from MicroStrategy. The company is based in Tysons, Virginia.

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

ALRM vs BCRX — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.6× larger
BCRX
$406.6M
$261.7M
ALRM
Growing faster (revenue YoY)
BCRX
BCRX
+201.1% gap
BCRX
209.1%
8.0%
ALRM
Higher net margin
BCRX
BCRX
47.2% more per $
BCRX
60.5%
13.2%
ALRM
More free cash flow
BCRX
BCRX
$256.1M more FCF
BCRX
$291.2M
$35.1M
ALRM
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
8.3%
ALRM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALRM
ALRM
BCRX
BCRX
Revenue
$261.7M
$406.6M
Net Profit
$34.6M
$245.8M
Gross Margin
66.0%
97.7%
Operating Margin
13.4%
64.0%
Net Margin
13.2%
60.5%
Revenue YoY
8.0%
209.1%
Net Profit YoY
14.8%
1017.5%
EPS (diluted)
$0.66
$1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALRM
ALRM
BCRX
BCRX
Q4 25
$261.7M
$406.6M
Q3 25
$256.4M
$159.4M
Q2 25
$254.3M
$163.4M
Q1 25
$238.8M
$145.5M
Q4 24
$242.2M
$131.5M
Q3 24
$240.5M
$117.1M
Q2 24
$233.8M
$109.3M
Q1 24
$223.3M
$92.8M
Net Profit
ALRM
ALRM
BCRX
BCRX
Q4 25
$34.6M
$245.8M
Q3 25
$35.1M
$12.9M
Q2 25
$34.2M
$5.1M
Q1 25
$27.7M
$32.0K
Q4 24
$30.1M
$-26.8M
Q3 24
$36.7M
$-14.0M
Q2 24
$33.5M
$-12.7M
Q1 24
$23.6M
$-35.4M
Gross Margin
ALRM
ALRM
BCRX
BCRX
Q4 25
66.0%
97.7%
Q3 25
65.8%
98.6%
Q2 25
65.6%
98.3%
Q1 25
67.2%
96.9%
Q4 24
65.5%
95.4%
Q3 24
64.8%
97.3%
Q2 24
65.2%
98.4%
Q1 24
65.7%
98.6%
Operating Margin
ALRM
ALRM
BCRX
BCRX
Q4 25
13.4%
64.0%
Q3 25
14.4%
18.6%
Q2 25
12.6%
18.2%
Q1 25
12.4%
14.6%
Q4 24
12.7%
-3.4%
Q3 24
13.8%
6.6%
Q2 24
11.0%
8.0%
Q1 24
8.4%
-15.6%
Net Margin
ALRM
ALRM
BCRX
BCRX
Q4 25
13.2%
60.5%
Q3 25
13.7%
8.1%
Q2 25
13.5%
3.1%
Q1 25
11.6%
0.0%
Q4 24
12.4%
-20.4%
Q3 24
15.3%
-12.0%
Q2 24
14.3%
-11.6%
Q1 24
10.6%
-38.1%
EPS (diluted)
ALRM
ALRM
BCRX
BCRX
Q4 25
$0.66
$1.13
Q3 25
$0.65
$0.06
Q2 25
$0.63
$0.02
Q1 25
$0.52
$0.00
Q4 24
$0.56
$-0.13
Q3 24
$0.67
$-0.07
Q2 24
$0.62
$-0.06
Q1 24
$0.44
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALRM
ALRM
BCRX
BCRX
Cash + ST InvestmentsLiquidity on hand
$960.6M
$274.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$848.2M
$-119.2M
Total Assets
$2.1B
$514.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALRM
ALRM
BCRX
BCRX
Q4 25
$960.6M
$274.7M
Q3 25
$1.1B
$212.9M
Q2 25
$1.0B
$260.0M
Q1 25
$1.2B
$295.1M
Q4 24
$1.2B
$320.9M
Q3 24
$1.2B
$96.8M
Q2 24
$1.1B
$78.4M
Q1 24
$747.9M
$84.3M
Stockholders' Equity
ALRM
ALRM
BCRX
BCRX
Q4 25
$848.2M
$-119.2M
Q3 25
$827.2M
$-387.9M
Q2 25
$797.3M
$-421.6M
Q1 25
$759.6M
$-451.9M
Q4 24
$726.5M
$-475.9M
Q3 24
$690.3M
$-468.6M
Q2 24
$645.5M
$-475.6M
Q1 24
$728.1M
$-476.2M
Total Assets
ALRM
ALRM
BCRX
BCRX
Q4 25
$2.1B
$514.2M
Q3 25
$2.1B
$446.4M
Q2 25
$2.1B
$457.2M
Q1 25
$2.1B
$480.0M
Q4 24
$2.0B
$490.4M
Q3 24
$2.0B
$491.3M
Q2 24
$1.9B
$472.4M
Q1 24
$1.5B
$467.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALRM
ALRM
BCRX
BCRX
Operating Cash FlowLast quarter
$35.9M
$292.0M
Free Cash FlowOCF − Capex
$35.1M
$291.2M
FCF MarginFCF / Revenue
13.4%
71.6%
Capex IntensityCapex / Revenue
0.3%
0.2%
Cash ConversionOCF / Net Profit
1.04×
1.19×
TTM Free Cash FlowTrailing 4 quarters
$137.0M
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALRM
ALRM
BCRX
BCRX
Q4 25
$35.9M
$292.0M
Q3 25
$70.6M
$41.6M
Q2 25
$22.7M
$41.3M
Q1 25
$24.1M
$-27.5M
Q4 24
$56.3M
$-5.2M
Q3 24
$77.3M
$8.2M
Q2 24
$23.0M
$-1.4M
Q1 24
$49.9M
$-53.7M
Free Cash Flow
ALRM
ALRM
BCRX
BCRX
Q4 25
$35.1M
$291.2M
Q3 25
$65.9M
$40.3M
Q2 25
$18.2M
$41.1M
Q1 25
$17.9M
$-27.7M
Q4 24
$54.0M
$-5.9M
Q3 24
$74.5M
$8.2M
Q2 24
$21.0M
$-1.5M
Q1 24
$46.8M
$-53.9M
FCF Margin
ALRM
ALRM
BCRX
BCRX
Q4 25
13.4%
71.6%
Q3 25
25.7%
25.3%
Q2 25
7.1%
25.2%
Q1 25
7.5%
-19.0%
Q4 24
22.3%
-4.5%
Q3 24
31.0%
7.0%
Q2 24
9.0%
-1.4%
Q1 24
21.0%
-58.1%
Capex Intensity
ALRM
ALRM
BCRX
BCRX
Q4 25
0.3%
0.2%
Q3 25
1.9%
0.8%
Q2 25
1.8%
0.1%
Q1 25
2.6%
0.1%
Q4 24
0.9%
0.5%
Q3 24
1.2%
0.1%
Q2 24
0.9%
0.1%
Q1 24
1.4%
0.3%
Cash Conversion
ALRM
ALRM
BCRX
BCRX
Q4 25
1.04×
1.19×
Q3 25
2.01×
3.23×
Q2 25
0.66×
8.12×
Q1 25
0.87×
-859.91×
Q4 24
1.87×
Q3 24
2.11×
Q2 24
0.69×
Q1 24
2.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALRM
ALRM

License And Service$180.2M69%
Hardwareand Other Revenue$81.4M31%

BCRX
BCRX

Segment breakdown not available.

Related Comparisons